6-{4-[2-(trifluoromethyl)phenoxy]piperidin-1-yl}pyridazine-3-carboxylic acid | 921605-78-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 6-{4-[2-(trifluoromethyl)phenoxy]piperidin-1-yl}pyridazine-3-carboxylic acid
• 英文别名: 6-(4-(2-(Trifluoromethyl)phenoxy)piperidin-1-yl)pyridazine-3-carboxylic acid；6-[4-[2-(trifluoromethyl)phenoxy]piperidin-1-yl]pyridazine-3-carboxylic acid
• CAS: 921605-78-9
• 化学式: C₁₇H₁₆F₃N₃O₃
• 分子量: 367.328
• InChiKey: MNXDTRVZLJPQQT-UHFFFAOYSA-N

物化性质

• 沸点：
  580.1±50.0 °C(Predicted)
• 密度：
  1.393±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  26
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.35
• 拓扑面积：
  75.6
• 氢给体数：
  1
• 氢受体数：
  9

反应信息

• 作为反应物：
  描述：

  6-{4-[2-(trifluoromethyl)phenoxy]piperidin-1-yl}pyridazine-3-carboxylic acid 在 氯化亚砜 作用下， 反应 1.0h， 生成
  参考文献：
  名称：

  WO2007/9236

  摘要：

  公开号：
• 作为产物：
  描述：

  methyl 6-{4-[2-(trifluoromethyl)phenoxy]piperidin-1-yl}pyridazine-3-carboxylate 在 甲醇 、 lithium hydroxide 、 水 、 盐酸 作用下， 以 四氢呋喃 、 甲醇 、 水 为溶剂， 反应 48.0h， 生成 6-{4-[2-(trifluoromethyl)phenoxy]piperidin-1-yl}pyridazine-3-carboxylic acid
  参考文献：
  名称：

  WO2007/9236

  摘要：

  公开号：

文献信息

• [EN] HETEROCYCLIC DERIVATIVES AND THEIR USE AS MEDIATORS OF STEAROYL-COA DESATURASE<br/>[FR] DERIVES HETEROCYCLIQUES ET LEUR UTILISATION EN TANT QUE MODULATEURS DE STEAROYLE-COA DESATURASE
  申请人：XENON PHARMACEUTICALS INC

  公开号：WO2006034338A1

  公开（公告）日：2006-03-30

  Methods of treating an SCD-mediated disease or condition in a mammal, preferably a human, are disclosed, wherein the methods comprise administering to a mammal in need thereof a compound of formula (I): Formula (I) where x, y, G, J, L, M, V, W, R2, R3, R4, R5, R5a, R6, R6a, R7, R7a, R8 and R8a are defined herein. Pharmaceutical compositions comprising the compounds of formula (I) are also disclosed.

  本发明揭示了治疗哺乳动物，尤其是人类患有SCD介导的疾病或症状的方法，其中所述方法包括向需要的哺乳动物施用以下化合物（I）的方法：化合物（I）其中x、y、G、J、L、M、V、W、R2、R3、R4、R5、R5a、R6、R6a、R7、R7a、R8和R8a在此处被定义。还揭示了包含化合物（I）的药物组合物。
• Heterocyclic Derivatives and Their Use as Mediators of Stearoyl-Coa Desaturase
  申请人：Kamboj Rajender

  公开号：US20070299081A1

  公开（公告）日：2007-12-27

  Methods of treating an SCD-mediated disease or condition in a mammal, preferably a human, are disclosed, wherein the methods comprise administering to a mammal in need thereof a compound of formula (I): Formula (I) where x, y, G, J, L, M, V, W, R 2 , R 3 , R 4 , R 5 , R 5a , R 6 , R 6a , R 7 , R 7a , R 8 , and R 8a are defined herein. Pharmaceutical compositions comprising the compounds of formula (I) are also disclosed.

  本发明揭示了治疗哺乳动物，特别是人类SCD介导的疾病或病状的方法，其中方法包括向需要该方法的哺乳动物施用式(I)的化合物：式(I)中x、y、G、J、L、M、V、W、R2、R3、R4、R5、R5a、R6、R6a、R7、R7a、R8和R8a如本文所定义。还揭示了包含式(I)的化合物的药物组合物。
• Heteroaromatic Compounds as Inhibitors of Stearoyl-Coenzyme a Delta-9 Desaturase
  申请人：Deschenes Denis

  公开号：US20090088431A1

  公开（公告）日：2009-04-02

  Heteroaromatic compounds of structural formula (I) are selective inhibitors of stearoyl-coenzyme A delta-9 desaturase (SCD1) relative to other known stearoyl-coenzyme A desaturases. The compounds of the present invention are useful for the prevention and treatment of conditions related to abnormal lipid synthesis and metabolism, including cardiovascular disease, such as atherosclerosis; lipid disorders; obesity; diabetes; neurological disease; metabolic syndrome; insulin resistance; fatty liver disease and cancer.

  结构式（I）的杂环芳香化合物相对于其他已知的硬脂酰辅酶A脱饱和酶（SCD1）是选择性抑制剂。本发明的化合物可用于预防和治疗与异常脂质合成和代谢有关的疾病，包括心血管疾病，如动脉粥样硬化；脂质紊乱；肥胖症；糖尿病；神经系统疾病；代谢综合症；胰岛素抵抗；脂肪肝病和癌症。
• Heteroaromatic Compounds As Inhibitors Of Stearoyl-Coenzyme A Delta-9 Desaturase
  申请人：Black Cameron

  公开号：US20090118296A1

  公开（公告）日：2009-05-07

  Heteroaromatic compounds of structural formula (I) are selective inhibitors of stearoyl-coenzyme A delta-9 desaturase (SCD1) relative to other known stearoyl-coenzyme A desaturases. The compounds of the present invention are useful for the prevention and treatment of conditions related to abnormal lipid synthesis and metabolism, including cardiovascular disease; atherosclerosis; lipid disorders; obesity; diabetes; neurological disease; metabolic syndrome; insulin resistance; and fatty liver disease.

  结构式（I）的杂环芳香化合物是选择性的硬脂酰辅酶A-Δ9-脱饱和酶（SCD1）抑制剂，相对于其他已知的硬脂酰辅酶A脱饱和酶。本发明的化合物对于预防和治疗与异常脂质合成和代谢有关的疾病非常有用，包括心血管疾病、动脉粥样硬化、脂质代谢紊乱、肥胖症、糖尿病、神经系统疾病、代谢综合征、胰岛素抵抗和脂肪肝病。
• Heteroaromatic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase
  申请人：Merck Frosst Canada Ltd.

  公开号：US07799787B2

  公开（公告）日：2010-09-21

  Heteroaromatic compounds of structural formula (I) are selective inhibitors of stearoyl-coenzyme A delta-9 desaturase (SCD1) relative to other known stearoyl-coenzyme A desaturases. The compounds of the present invention are useful for the prevention and treatment of conditions related to abnormal lipid synthesis and metabolism, including cardiovascular disease, such as atherosclerosis; lipid disorders; obesity; diabetes; neurological disease; metabolic syndrome; insulin resistance; fatty liver disease and cancer.

  结构式（I）的杂环芳香化合物是选择性抑制硬脂酰辅酶A delta-9去饱和酶（SCD1）相对于其他已知的硬脂酰辅酶A去饱和酶。本发明的化合物对于预防和治疗与异常脂质合成和代谢相关的疾病非常有用，包括心血管疾病，如动脉粥样硬化;脂质代谢紊乱;肥胖;糖尿病;神经系统疾病;代谢综合征;胰岛素抵抗;脂肪肝病和癌症。